» Articles » PMID: 30669675

Murine Models of Acute Myeloid Leukaemia

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Jan 24
PMID 30669675
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukaemia (AML) is a rare but severe form of human cancer that results from a limited number of functionally cooperating genetic abnormalities leading to uncontrolled proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Before the identification of genetic driver lesions, chemically, irradiation or viral infection-induced mouse leukaemia models provided platforms to test novel chemotherapeutics. Later, transgenic mouse models were established to test the in vivo transforming potential of newly cloned fusion genes and genetic aberrations detected in patients' genomes. Hereby researchers constitutively or conditionally expressed the respective gene in the germline of the mouse or reconstituted the hematopoietic system of lethally irradiated mice with bone marrow virally expressing the mutation of interest. More recently, immune deficient mice have been explored to study patient-derived human AML cells in vivo. Unfortunately, although complementary to each other, none of the currently available strategies faithfully model the initiation and progression of the human disease. Nevertheless, fast advances in the fields of next generation sequencing, molecular technology and bioengineering are continuously contributing to the generation of better mouse models. Here we review the most important AML mouse models of each category, briefly describe their advantages and limitations and show how they have contributed to our understanding of the biology and to the development of novel therapies.

Citing Articles

Enhancing Gene Delivery in NB-4 Cells: Overcoming Transduction and Selection Challenges.

Leto S, Gehlot S, Sheth B, Ratti S, Manzoli L, Divecha N Cells. 2024; 13(22).

PMID: 39594598 PMC: 11593156. DOI: 10.3390/cells13221849.


Leukemia circulation kinetics revealed through blood exchange method.

Miller A, Rodriguez F, Langenbucher A, Lin L, Bray C, Duquette S Commun Biol. 2024; 7(1):483.

PMID: 38643279 PMC: 11032325. DOI: 10.1038/s42003-024-06181-x.


Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.


Joint representation and visualization of derailed cell states with Decipher.

Nazaret A, Fan J, Lavallee V, Burdziak C, Cornish A, Kiseliovas V bioRxiv. 2023; .

PMID: 38014231 PMC: 10680623. DOI: 10.1101/2023.11.11.566719.


PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia.

Carlock C, Bai Y, Paige-Hood A, Li Q, Nguele Meke F, Zhang Z JCI Insight. 2023; 8(19).

PMID: 37665633 PMC: 10619439. DOI: 10.1172/jci.insight.170065.


References
1.
Olme C, Finnon R, Brown N, Kabacik S, Bouffler S, Badie C . Live cell detection of chromosome 2 deletion and Sfpi1/PU1 loss in radiation-induced mouse acute myeloid leukaemia. Leuk Res. 2013; 37(10):1374-82. PMC: 3775122. DOI: 10.1016/j.leukres.2013.05.019. View

2.
Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D . FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007; 12(4):367-80. PMC: 2104473. DOI: 10.1016/j.ccr.2007.08.031. View

3.
McCormack E, Bruserud O, Gjertsen B . Review: genetic models of acute myeloid leukaemia. Oncogene. 2008; 27(27):3765-79. DOI: 10.1038/onc.2008.16. View

4.
Chu M, Fischer G . A proposed mechanism of action of 1-beta-D-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells. Biochem Pharmacol. 1962; 11:423-30. DOI: 10.1016/0006-2952(62)90225-3. View

5.
Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View